Literature DB >> 30187438

Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol.

Fabio Caputo1,2, Roberta Agabio3, Teo Vignoli4, Valentino Patussi5, Tiziana Fanucchi5, Paolo Cimarosti6, Cristina Meneguzzi6, Giovanni Greco7, Raffaella Rossin8, Michele Parisi9, Davide Mioni10, Sarino Arico'11, Vincenzo Ostilio Palmieri12, Valeria Zavan13, Pierluigi Allosio14, Patrizia Balbinot15, Maria Francesca Amendola16, Livia Macciò17, Doda Renzetti18, Emanuele Scafato19, Gianni Testino15.   

Abstract

The chronic use of alcohol can lead to the onset of an alcohol use disorder (AUD). About 50% of subjects with an AUD may develop alcohol withdrawal syndrome (AWS) when they reduce or discontinue their alcohol consumption and, in 3-5% of them, convulsions and delirium tremens (DTs), representing life-threatening complications, may occur. Unfortunately, few physicians are adequately trained in identifying and treating AWS. The Italian Society on Alcohol has, therefore, implemented a task force of specialists to draw up recommendations for the treatment of AWS with the following main results: (1) while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated; (2) out-patient treatment is appropriate in patients with mild or moderate AWS, while patients with severe AWS need to be treated as in-patients; (3) benzodiazepines, BDZs are the "gold standard" for the treatment of AWS and DTs; (4) alpha-2-agonists, beta-blockers, and neuroleptics may be used in association when BDZs do not completely resolve specific persisting symptoms of AWS; (5) in the case of a refractory form of DTs, the use of anaesthetic drugs (propofol and phenobarbital) in an intensive care unit is appropriate; (6) alternatively to BDZs, sodium oxybate, clomethiazole, and tiapride approved in some European Countries for the treatment of AWS may be employed for the treatment of moderate AWS; (7) anti-convulsants are not sufficient to suppress AWS, and they may be used only in association with BDZs for the treatment of refractory forms of convulsions in the course of AWS.

Entities:  

Keywords:  Acute alcohol intoxication; Alcohol withdrawal syndrome; Pharmacological treatment

Mesh:

Substances:

Year:  2018        PMID: 30187438     DOI: 10.1007/s11739-018-1933-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  5 in total

1.  Lormetazepam in oral solution: a formulation at risk of high-dose use.

Authors:  Fiammetta Cosci; Antonio Egidio Nardi; Vladan Starcevic; Guy Chouinard; Richard Balon
Journal:  Intern Emerg Med       Date:  2019-07-03       Impact factor: 3.397

2.  Mortality and its association with chronic alcohol-related diseases in patients admitted to the emergency department for acute alcoholic intoxication: retrospective cohort study.

Authors:  Francesco Palmese; Maria Elena Bonavita; Giorgio Bedogni; Marco Domenicali; Enrico Pompili; Maria Teresa Migliano; Nicola Reggidori; Cecilia Di Stefano; Marta Grieco; Stefano Colazzo; Manuel Tufoni; Maurizio Baldassarre; Paolo Caraceni; Francesco Giuseppe Foschi; Fabrizio Giostra; Gabriele Farina; Rossella Del Toro
Journal:  Intern Emerg Med       Date:  2022-10-05       Impact factor: 5.472

3.  Can oral formulation increase the risk of lormetazepam abuse?

Authors:  Enrico Costa; Enrico Sterzi; Federico Tedeschi; Rebecca Casari; Paola Marini; Fabio Lugoboni
Journal:  Intern Emerg Med       Date:  2020-10-23       Impact factor: 3.397

4.  Delusional Parasitosis in a Patient with Alcohol-induced Psychotic Disorder.

Authors:  Blayne Knapp; Emmanuel Tito; Eduardo D Espiridion
Journal:  Cureus       Date:  2019-03-29

5.  The impact of the COVID-19 pandemic on alcohol-related emergency department visits in the Netherlands: The ALCOVID study.

Authors:  Femke M F M Knapen; Susanne J M Laumer; Frits H M Van Osch; Dennis G Barten
Journal:  Drug Alcohol Rev       Date:  2021-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.